Intervacc AB (publ) IVACC

Updated: 10 Aug 2026

First North | Biotech | Veterinary medicine and animal vaccines

No signal published yet

We already track Intervacc and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Intervacc free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
First North
Type
Biotech
Sector
Veterinary medicine and animal vaccines
We're already tracking Intervacc AB (publ) — here are the latest events we've registered

Recent News

  • On July 29, 2026, Intervacc announced that Strangvac was approved for import into New Zealand under a Special Circumstances Permit following strangles outbreaks in the region. On July 30, 2026, the company submitted a Type II variation application to the European Medicines Agency (EMA) seeking to extend the duration of immunity for Strangvac to 12 months.

What Firelda Watch includes for Intervacc AB (publ)

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Intervacc AB (publ) will be delivered in the same format.

Want to follow Intervacc AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Intervacc free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Intervacc AB (publ) IVACC
Intervacc — follow and we'll monitor it
Follow Intervacc free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.